Pfizer's rare disease drug succeeds in late-stage study

March 29 (Reuters) - Pfizer Inc said on Thursday its drug for a rare and fatal disease associated with progressive heart failure met the main goal in a late-stage study.

The company said the drug, tafamidis, showed statistically significant reduction in deaths and frequency of cardiovascular-related hospitalizations compared to a placebo at 30 months. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)